Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Vipin K. Garg Ph.D. | President, CEO & Director | 19.52M | -- | 1958 |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer | 13.49M | -- | 1953 |
| Mr. Raymond M. Jordt M.B.A. | Chief Business Officer | 11.46M | -- | 1973 |
| Mr. Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer | -- | -- | 1956 |
| Mr. Andrew Shutterly M.S. | Principal Financial & Accounting Officer and Corporate Controller | -- | -- | 1988 |
| Mr. Bertrand Georges Ph.D. | Chief Technology Officer | -- | -- | -- |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer | 11.86M | -- | 1959 |
| Mr. Tony Blandin B.S. | Vice President of Quality & Compliance Management | -- | -- | -- |
Altimmune, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 59
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Corporate Governance
Upcoming Events
November 12, 2024 at 12:00 PM UTC
Altimmune, Inc. Earnings Date
Recent Events
Recent Events Information Not Available